会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CELL-PROLIFERATIVE DISORDER TREATMENTS USING CRE DECOY OLIGOMERS, BCL-2 ANTISENSE AND HYBRID OLIGOMERS
    • 细胞增殖性疾病使用CRE DECOY OLIGOMERS,BCL-2抗体和混合寡聚体
    • WO02057480A3
    • 2003-07-24
    • PCT/US0201967
    • 2002-01-22
    • GENTA INCKLEM ROBERT E
    • KLEM ROBERT E
    • A61K38/00A61K48/00C07H21/02C12N15/113C12Q1/68C07H21/04C12N15/63C12N15/85C12P19/34
    • C12N15/113A61K38/00C07K2319/00C12N15/1135C12N2310/13C12N2310/315C12N2310/53
    • The present invention is directed to hybrid oligomers comprising a cyclic AMP response element CRE sequence and a sequence that hybridizes to a bcl-2 pre-mRNA or mRNA, and pharmaceutical compositions comprising such hybrids. The present invention is also directed to the use of CRE decoy oligomers, comprising a CRE consensus sequence, and bcl-2 antisense oligomers in combination therapies, and the use of bcl-2/CRE hybrid oligomers, to treat or prevent cell-proliferative related disorders, including hyperplasias, cancers, tumors and carcinomas. In one embodiment, the invention relates to therapeutic protocols comprising the administration of a CRE decoy oligomer and a bcl-2 antisense oligomer for the treatment of cell-proliferative related disorders. In another embodiment, the invention relates to therapeutic protocols comprising the administration of a bcl-2 antisense/CRE decoy bcl-2/CRE hybrid oligomer for the treatment of cell-proliferative related disorders.
    • 本发明涉及包含环AMP响应元件CRE序列和与bcl-2前mRNA或mRNA杂交的序列的杂交寡聚体,以及包含这种杂交体的药物组合物。 本发明还涉及包含CRE共有序列的CRE诱饵低聚物和联合治疗中的bcl-2反义寡聚体的用途,以及使用bcl-2 / CRE杂合寡聚体来治疗或预防细胞增殖相关 疾病,包括增生,癌症,肿瘤和癌。 在一个实施方案中,本发明涉及包括施用CRE诱饵寡聚体和bcl-2反义寡聚体用于治疗细胞增殖性相关疾病的治疗方案。 在另一个实施方案中,本发明涉及治疗方案,其包括施用bcl-2反义/ CRE诱饵bcl-2 / CRE杂合寡聚体用于治疗细胞增殖相关病症。